Autonomous in vitro growth of myeloid leukemic colony-
Introduction
Acute myeloid leukemia (AML)' is a highly proliferative disease with a fatal outcome in most cases. Mechanisms enabling malignant cells in AML to escape physiologic growth restrictions are largely unknown. Previously, it has been shown that blast cells of patients with AML proliferate in response to exogenous colony-stimulating factors (CSF) both in vitro (1) (2) (3) and in vivo (4) . AML blasts were also shown to secrete various CSFs and use these factors as autocrine growth stimu- 1 . Abbreviations used in this paper: AML, acute myelogenous leukemia; AML-CM, AML conditioned medium; CSF, colony-stimulating factor(s); EC, endothelial cell(s); G, granulocyte; GM, granulocyte/ macrophage; L-CFC, leukemic colony-forming cells; M, macrophage; MNC, mononuclear cells; Mo, monocytes; SRBC, sheep red blood cells; TNF, tumor necrosis factor.
lators (5) (6) (7) (8) (9) . Recent data support the concept that various cytokines may act in concert to induce optimal leukemic growth (1) (2) (3) (5) (6) (7) (8) (9) . , also referred to as IL-beta-2 or B cell stimulatory factor 2 (10, I 1) has been found to exhibit synergistic growthpromoting activity with IL-3 by enhancing IL-3-dependent proliferation of multipotential hematopoietic progenitor cells (12, 13) . The mode of action of IL-6 in the regulation of leukemic growth has not been determined yet.
It has been shown that AML blasts may also recruit nontransformed accessory cells to provide growth-promoting molecules for the leukemic clone. Of interest in this regard is the observation of secretion of IL-1 by some AML populations with the potential to induce CSF secretion by endothelial cells (EC), suggesting involvement of a paracrine loop in the stimulation of leukemic growth (14) .
Tumor necrosis factor (TNF)-alpha, so far not known to be constitutively produced by fresh AML blasts, has been recognized as a potent inducer ofCSF production by accessory bone marrow cells, including EC, fibroblasts, and monocytes (Mo) (15, 16) , but has also been shown to inhibit clonogenic growth of AML cells in a dose-dependent fashion when acting directly on leukemic colony-forming cells (L-CFC) (17, 18) .
The present investigation was initiated to study production of the cytokines IL-6, TNF-alpha, and IL-1-beta by AML blasts to gain further insights into the role ofthese molecules in autoregulatory control of leukemia growth. We show that AML blast cells produce biologically active IL-6, TNF-alpha, and IL-I beta. AML-derived TNF-alpha has the capacity to induce granulocyte/macrophage-and granulocyte-CSF (GM-and G-CSF) production by endothelial cells and may therefore support leukemia growth via a paracrine pathway, whereas IL-6, released by AML cells, is shown to act as a costimulator for autonomous L-CFC proliferation.
Methods
Source of leukemic cells. Highly purified leukemic peripheral blood samples (> 90% blast cells by morphology) were obtained from consenting patients with AML. The diagnosis was established by morphology according to French-American-British criteria (19) , cytochemical staining, and immunofluorescence analysis, using a panel of MAbs (20) . Low (23) antibody to improve the enrichment of GM-CFU. Ia-positive cells were then assayed for CFU-GM as described above.
Culture condition for EC. EC were isolated from human umbilical cord veins by an adaptation of a previously described method (24). In all experiments, passage 4-6 EC that were grown in medium 199 (Gibco Laboratories) containing 20% FCS, heparin (2 U/ml), and endothelial growth factor (25 ,g/ml; Sigma Chemical GmbH) were used.
Media conditioned by AML blasts secreting TNF-alpha or IL-6 were added to EC cultures in a concentration of 20% (vol/vol). Incubation period of EC cultures was 6 h before RNA extraction and 24 h before testing culture supernatants in CFU-GM assays.
Biological assayfor IL-6. IL-6 secreted by AML blasts was quantitated in a proliferation assay with the IL-6-dependent hybridoma cell line B1 3.29 (subline B9) essentially as described (25) . Samples to be tested were titrated in twofold dilutions and related to an internal standard preparation produced by Dr. Hirano IL-I ELISA. An ELISA specific for IL-1-beta was obtained from Cistron, Pine Brook, NJ. Sensitivity was shown to be 0.1 ng/ml or 2 U/ml. No crossreactivity was apparent with IL-l-alpha or TNF-alpha.
TNF-RIA. An RIA specific for TNF-alpha was kindly provided by Dr. G. Lambelin, IRE-Medgenix, Fleurus, Belgium. Sensitivity was shown to be 0.02 ng/ml TNF at 10% tracer binding inhibition.
Northern blot analysis. Total cellular RNA was prepared from leukemic blast cells or normal low density bone marrow MNC or cultured EC using the guanidinium isothiocyanate/cesium chloride method (26) . After glyoxylation, 10-,sg samples of RNA were size-fractionated by agarose gel electrophoresis and transferred to synthetic membranes (Schleicher & Schuell. Dassel, FRG). Filters were hybridized with different DNA probes and radiolabeled as described previously (27) , each specific for either TNF-alpha (kindly provided by Genentech Corp., San Francisco, CA), IL-6 (produced by Dr. Hirano and Dr. Kishimoto), G-CSF (kindly provided by L. Souza, Amgen Biologicals, Thousand Oaks, CA), GM-CSF (kindly provided by D. Krumwieh, Behringwerke, Marburg, FRG), or M-CSF (kindly provided by P. Ralph, Cetus Corp., Berkeley, CA). IL-I-beta oligonucleotide probe 
Results
Highly enriched blast cell populations of patients with AML were investigated for gene expression of the cytokines IL-6 (n = 54), TNF-alpha (n = 54), and IL-1-beta (n = 44). 14 AML samples revealed cytoplasmic mRNA for IL-6, 19 for TNFalpha, and 14 for IL-l-beta (Fig. 1, A-C and Table I ). mRNA accumulation for IL-6, TNF-alpha, and IL-I-beta was always associated with the release of the corresponding proteins by AML blasts into their culture supernatants (Table I) Tables I and II) . IL-l-beta expression was found in AML exclusively in combination with TNF-alpha (n = 9) or with TNF-alpha plus IL-6 (n = 5) ( Table II) . 19 (Tables I and III) . Expression of multilineage-CSF (IL-3) could not be detected in this series of AML samples (Table III) .
The remaining 9 of these 28 AML, which showed cytokine expression, failed to express CSF. Five synthesized TNF-alpha only (cases 8, 9, 37, 39, and 50) and four IL-6 only (cases 5, 17, 31, and 47) (Tables I and III). AML samples not producing CSF on their own were studied for their ability to induce accessory cells to release CSF by self-produced TNF-alpha or IL-6. To this end, individual supernatants of five CSF-negative AML (cases 5, 8, 39, 47, and 50) were added to EC cultures. After an incubation period of 6 h, EC were studied by Northern blot analysis for accumulation of CSF mRNA. Inducible synthesis of GM-and G-CSF mRNA was found in EC that had been exposed to supernatants ofAML samples derived from patients 8, 39, and 50 (Fig.  2 , B and C, Table IV ). All three AML specimens produced TNF-alpha (Fig. 2 A, Table I ). Table III Synthesis of GM-and G-CSF could not be induced in EC that were exposed to supernatants obtained from AML samples of patients 5 and 47, which had been shown to synthesize IL-6 only ( Fig. 2 A, Tables I and IV) .
Induction of GM-and G-CSF expression in EC by TNFalpha-containing AML supernatants could be prevented by treatment of supernatants with a neutralizing MAb to TNFalpha (Table IV) . Supernatants collected from five AML specimens (cases 13, 19, 26, 41, and 49) that produced neither CSF nor any ofthe cytokines investigated (Table I) we could not detect CSF mRNA synthesis by EC in these selected experiments (data not shown).
Four AML samples (cases 3, 33, 35, and 54), producing one or multiple CSF species and displaying autonomous in vitro colony growth, failed to produce IL-i-beta, TNF-alpha, and IL-6. These samples were used to study effects of IL-1-beta, TNF-alpha, and IL-6 on colony formation by L-CFC. Augmentation of L-CFC growth could be achieved in cultures that were treated with IL-6 but not in cultures treated with TNF-alpha or IL-I -beta (Table V) . These data suggest a role of 
Discussion
A possible role of hematopoietic growth factors in the control of proliferation and differentiation of AML blasts has been reported by several groups (1-3, 5-9, and 28). Proliferation of most L-CFC in response to one or several CSF species has been recognized (1-9). Recent evidence for constitutive production of various CSF (i.e., G-, GM-, and M-CSF) by AML blasts and for autonomous in vitro growth of some AML suggests that autocrine growth stimulatory loops may operate in AML (1, 2, 5) .
However, it is unlikely that deficiency or overexpression of a single factor explains the transforming event taking place in hematopoietic malignancies, particularly since hematopoiesis involves both inhibitory and synergistic activities (9, 29) . The aim of this study was to further characterize cytokine involvement in the pathophysiology of acute myeloblastic leukemia, particularly by focusing on IL-6, TNF-alpha, and IL-1-beta.
IL-6 is produced by activated monocytes, fibroblasts, and, to a lesser extent, lymphocytes (10, 11, 30) . Its expression in diploid fibroblasts was found to be inducible by TNF-alpha, IL-1, and platelet derived growth factor (31) (32) (33) (34) (35) . TNF-alphainduced synthesis of IL-6 by fibroblasts was previously interpreted as a physiologic negative feedback mechanism, regulating TNF-mediated fibroblast proliferation (31) . Moreover, IL-6 appears to exert multiple biological functions in addition to its growth inhibitory activity on human fibroblasts (11). IL-6 displays antiviral activity (36, 37) and acts as a growth factor for certain mouse hybridomas and mouse myelomas (38) , as a differentiation factor for human B cells (39) , and as an inducer of acute phase proteins in hepatocytes (40) .
IL-6 expression has also been reported in various human malignancies. IL-6 mRNA was found in IL-1-induced cells of the astrocytoma line U373 and the glioblastoma line SK-MG4 (41) . Constitutive expression of IL-6 was observed in several tumor cells including cardiac myxomas (10, 39, 42) or bladder carcinomas (10, 42; unpublished results). Most remarkable was the recent finding of IL-6 expression by multiple myeloma cells (43) . Inhibition of in vitro growth of myeloma cells by anti-IL-6 antibody has provided the first evidence to suggest an autocrine loop involved in growth promotion of human myelomas (43) . IL-6 was shown to synergistically induce growth of multipotential normal hematopoietic progenitor cells in concert with IL-3 (12, 13). These findings lead us to consider a possible role of IL-6 in the proliferation of leukemic blasts.
We show here that IL-6 is constitutively expressed in a substantial proportion of AML samples (25%). Moreover, constitutive production of TNF-alpha and IL-1-beta by AML cells is frequently detected in our series of leukemias (35 and 3 1%, respectively).
In five cases IL-6 expression by AML blasts is associated with the production of TNF-alpha and IL-1 -beta. However, it is unlikely that IL-6 secretion by AML blasts depends on en-dogenous induction by TNF-alpha or IL-I -beta, since the majority ofIL-6 positive AML samples fail to produce TNF-alpha and IL-I-beta. 19 of the 28 AML samples that show cytokine production of IL-I-beta, TNF-alpha, or IL-6 simultaneously coexpress Gor GM-CSF, mostly in combination with M-CSF. None ofthe AML samples tested had detectable levels of IL-3 mRNA.
Studying effects of IL-6, TNF-alpha, and IL-1-beta on CSF-driven autonomous L-CFC growth in vitro, synergistic actions with CSF on leukemic colony formation was only found for IL-6. Furthermore we studied the potential of TNF, present in AML-derived culture supernatants, to recruit accessory cells for CSF production. Similar mechanisms have recently been attributed to IL-l (14) . AML-produced TNF-alpha was found to induce accumulation of rmRNA for GM-and G-CSF by EC, suggesting that TNF-alpha may optimize CSFdependent AML growth via paracrine pathways.
Unregulated secretion of TNF-alpha and IL-1-beta by AML blasts may result in unrestricted production of CSF by microenvironmental bone marrow cells, whereas IL-6 may act as a cofactor to stimulate growth of leukemic targets. The cause of the constitutive cytokine expression in AML blasts will require further investigation. None of the cases investigated has morphologically detectable abnormalities of the chromosomes 2, 7, or 6, the locations ofthe IL-l-beta, IL-6, or TNF genes, respectively. Southern blot analysis of DNA from all patients, digested with the restriction enzymes Bgl I, Bam HI, Eco RI, and Hind DIII using specific DNA probes has not provided evidence for rearrangements or amplification of the respective cytokine genes (not shown). Failure of most of the AML samples investigated to express multiple cytokine genes simultaneously, makes an activation of common regulatory sequences rather unlikely. Moreover, preliminary observations in our laboratory demonstrating comparable transcriptional activities of genes for IL-l-beta, IL-6, and TNF-alpha in normal monocytes and selected AML samples suggest posttranscriptional regulation of these cytokines by AML.
